8/102 sources · 2 publishersUpdated Nov 16, 15:43 UTC
Aclaris Therapeutics begins Phase 2b trial of modzatinib for lichen planus
Aclaris Therapeutics announced the start of its Phase 2b ALPHA trial evaluating modzatinib in about 100 patients with moderate‑to‑severe lichen planus, beginning with an oral erosive cohort. The U.S. FDA granted Fast Track designation to the drug. Top‑line results from the oral erosive group are expected in the second half of 2027.
Why it matters
The Fast Track designation may accelerate regulatory review, which could be positive for the company's pipeline, but the stock fell 8.08% in pre‑market trading as investors priced in the trial risk.
Key facts
- 1Aclaris initiated a Phase 2b trial named ALPHA to test modzatinib in approximately 100 patients with moderate‑to‑severe lichen planus. tradingview.com
- 2The first cohort will enroll patients with oral erosive lichen planus. tradingview.com
- 3The U.S. FDA granted Fast Track designation to modzatinib for this indication. tradingview.com
- 4Top‑line results from the oral erosive cohort are expected in the second half of 2027. tradingview.com
- 5Aclaris stock was down 8.08% in pre‑market trading following the announcement. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.